

Session No.	#	Presentation Title	Name	Country	Affiliation
P25-1	Anti-infective drugs (1): Aminoglycosides and beta-lactams				
	1	Population pharmacokinetic modeling approach to compare different amikacin dose rates in children with cystic fibrosis: Are we efficient	Jean-Baptiste Woillard	France	CHU Limoges, Univ Limoges
	2	The effect of gentamicin peak concentration based dosing on gentamicin target attainment in critically ill patients	Reinier van Hest	The Netherlands	Academic Medical Center
	3	Tobramycin toxicity after use of antibiotic loaded cement	Penny D. Colbourne	Canada	University of Alberta Hospital
	4	External evaluation of amikacin population pharmacokinetic models in Japanese adult patients	Ken-ichi Sako	Japan	Nihon Pharmaceutical University
	5	A high performance liquid chromatography method for the determination of doripenem in human plasma and dialysate	Sirin Phenphinan	Thailand	Khon Kaen University
	6	Do prolonged infusions of imipenem protect against the effects of augmented renal clearance and obesity?	Jan Strojil	Czech Republic	Palacky University Olomouc
	7	A cohort study of therapeutic drug monitoring on Meropenem in ICU patients	Lu Jin	China	Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University, The Medical
	8	Highly variable absorption of clavulanic acid during the day: a population pharmacokinetic analysis	Femke de Velde	The Netherlands	Erasmus MC
9	PROSAB Study: Concentration of cefazolin and ciprofloxacin in prostate tissue	Erik Wilms	The Netherlands	Central Hospital Pharmacy The Hague	
P25-2	Anti-infective drugs (2): Beta-lactams				
	1	An UHPLC-HR-MS assay for beta-lactams in bronchoalveolar lava fluid	Alain Gaston Verstraete	Belgium	Ghent University Hospital and Ghent University
	2	Development of novel LCMSMS assay for therapeutic drug monitoring of five beta-lactam antibiotics in human plasma	Edwin Zhi Wei Ting	Singapore	Shimadzu (Asia Pacific) Pte Ltd.
	3	Simultaneous determination of nine beta-lactam antibiotics in human plasma by an ultrafast hydrophilic-interaction chromatography — tandem	Birgit C. P. Koch	The Netherlands	Erasmus MC
	4	Tandem LC-MS/MS method for the determination of Piperacillin (PIP) and Tazobactam (TAZ) in human plasma of patients in intensive care units who	Carsten Mueller	Germany	University Hospital of Cologne
	5	The SPIT study: correlation of saliva and plasma beta-lactam antibiotic concentrations in the intensive care unit	Sofie Colman	Belgium	Ghent University Hospital
	6	Population pharmacokinetic analysis of piperacillin and tazobactam by using their blood and urine level data in Japanese pediatric patients	Noriyuki Ishihara	Japan	Shimane University Hospital
	7	Pharmacokinetic and pharmacodynamic characterization of piperacillin-tazobactam, flomoxef and pazufloxacin in prostate tissue and plasma of	Akira Kuroda	Japan	Hiroshima University
	8	Broad spectrum beta-lactam antibiotic levels in critically ill Asian patients	Lawrence Soon-U Lee	Singapore	National University of Singapore
9	Tonic clonic generalized seizure in 6 years old boy in association with procaine penicillin injection: a variant of Hoigne's syndrome?	Hundie Tesfaye	Czech Republic	University Hospital Motol, Charles University	
P25-3	Anti-infective drugs (3): TB drugs				
	1	A proposal of an individualized dosage regimen of isoniazid in tuberculosis patients	Karim Aouam	Tunisia	University of Monastir
	2	Population pharmacokinetics of isoniazid in Tunisian tuberculosis patients based on routinely data	Karim Aouam	Tunisia	University of Monastir
	3	Adequacy of isoniazid and rifampicin in anti-tuberculosis treatment in children; a pharmacometric approach	Blessed Winston Aruldhas	India	Christian Medical College, Vellore
	4	A case report of rifampicin content in a red bezoar, which was found in a patient who took rifampicin for the treatment of pulmonary	Masami Kawahara	Japan	Kanazawa Municipal Hospital
	5	Development and validation of anti-TB drugs in plasma and tissue to support pharmacokinetic-driven studies	Mark A. Marzinke	United States of America	Johns Hopkins University
6	Meta-analysis of NAT2 genotypes and the risk for anti-tuberculosis induced liver injury (AT-DILI)	Supharat Suvichapanich	Japan	University of Tokyo	

Session No.	#	Presentation Title	Name	Country	Affiliation
P25-4	Anti-infective drugs (4): Vancomycin				
	1	Vancomycin PBPK modeling in special populations to elucidate case-based clinical PK observations	Chie Emoto	United States of America	Cincinnati Children's Hospital Medical Center
	2	Vancomycin trough concentrations alone might not be an accurate surrogate for AUC in clinical practice	Hana Suchankova	Czech Republic	Palacky University Olomouc
	3	Comparison of outcome of vancomycin by using different monitoring techniques between AUC/MIC and trough concentration in Thai	Pakwan Bunupuradah	Thailand	Ramathibodi Hospital, Mahidol University
	4	Population pharmacokinetic analysis of vancomycin in patients with hematopoietic stem cell transplantation	Akira Okada	Japan	Kobe Gakuin University
	5	Optimizing vancomycin dosage with a therapeutic drug monitoring program in thrice-weekly hemodialysis patients	Patricio Mas-Serrano	Spain	Hospital General Universitario de Alicante
	6	Large prediction errors of vancomycin simulation in ICU patients	Michiya Akabane	Japan	Shiga University of Medical Science Hospital
	7	Usefulness of the Bayesian estimation based TDM for vancomycin dose individualization in patients with continuous renal replacement therapy	Kazutaka Oda	Japan	Kumamoto University Hospital
	8	Therapeutic drug monitoring of vancomycin based on an HPLC method	Yi Zhou	China	The First Affiliated Hospital of Chongqing Medical University
	9	HPLC method for determination of vancomycin in cerebrospinal fluid	Eva Klapkova	Czech Republic	Charles University and University Hospital Motol
Withdrawn	10	Vancomycin and the true value	Eva Hoess	Germany	Roche Diagnostics GmbH
P25-5	Anti-infective drugs (5)				
	1	Development of an immunoassay-based point-of-care testing (POCT) device for therapeutic drug monitoring of vancomycin	Koichiro Tsuchiya	Japan	Tokushima University
	2	Combined dried blood spot analysis of vancomycin, tobramycin and creatinine using LC-MS/MS for monitoring outpatient parenteral	Evelien ter Weijden	The Netherlands	University Medical Center Utrecht
	3	Vancomycin-induced nephrotoxicity in mice	Masaki Takigawa	Japan	Tokyo Metropolitan Geriatric Hospital
	4	Pharmacokinetics of intrathecal administration of vancomycin in patients with infectious meningitis	Milada Halacova	Czech Republic	Na Homolce Hospital
	5	An evaluation of the effectivity of the current treatment of uncomplicated urinary tract infections with fosfomicin based on urinary concentrations in	Rixt Anna Wijma	The Netherlands	Erasmus MC
	6	AUC/MIC ratio used for therapeutic drug monitoring of levofloxacin after four different regimens	Matthieu Gregoire	France	University Hospital of Nantes
	7	Antimicrobial resistance pattern in a block primary health centre in India	Preeti Barnwal	India	Jamia Hamdard
P25-6	Immunosuppressive drugs (1): LC-MS/MS assay				
	1	Comparison of PETINIA and LC-MS/MS for determining plasma mycophenolic acid concentrations in Japanese lung transplant recipients	Masafumi Kikuchi	Japan	Tohoku University Hospital
	2	A validated UPLC-MS/MS method for intracellular tacrolimus concentrations	Brenda C. M. de Winter	The Netherlands	Erasmus MC
	3	An 8 second analytical method for Tacrolimus in whole blood by LDTD-MS/MS	Kamisha L. Johnson-Davis	United States of America	University of Utah Health Sciences Center and ARUP Institute for Clinical and
	4	UHPLC-MS/MS based determination of cyclosporine A, tacrolimus and everolimus in autologous serum eye drops for the treatment of ocular	Martin Helge Josef Wiesen	Germany	University of Cologne
	5	Fully automated platform for sensitive determination of immunosuppressant drugs in whole blood using high quality internal	Eishi Imoto	Japan	Shimadzu Corporation
	6	Simultaneous determination of 6-thioguanine nucleotides and 6-methylmercaptopurine in the red blood cells of patients with Crohn's	Xuemei Luo	China	Nanjing Drum Tower Hospital, The Affiliated Nanjing University Medical School
	7	Automated sample preparation of whole blood - the need for speed	Miguel Gambell Barroso	Sweden	Karolinska University Laboratory
	8	Pharmacokinetics and pharmacodynamics of tacrolimus into its target cells for the longitudinal follow up of liver transplant recipients: looking for new	Camille Tron	France	Rennes University Hospital
	9	Investigation of tacrolimus transport mechanisms into the white blood cells: Does only P-glycoprotein matter?	Camille Tron	France	Rennes University Hospital

Session No.	#	Presentation Title	Name	Country	Affiliation
P25-7	Immunosuppressive drugs (2): Monoclonal antibody and genotyping				
	1	Quantification of active infliximab in human serum with LC-MS/MS	Mohsin El Amrani	The Netherlands	University Medical Center Utrecht
	2	Determination of belatacept pharmacokinetics in renal transplant patients using a novel automated assay	Rolf Anton Klaasen	Norway	Oslo University Hospital
	3	Intra-patient variability in the pharmacokinetics of etanercept maintenance treatment	Teun van Gelder	The Netherlands	Erasmus MC
	4	A novel application for antibody quantitation method development and validation of infliximab in plasma by nSMOL and Skyline software	Song Yuling	China	Shimadzu (China) CO., LTD.
	5	Assay development toward Infliximab therapeutic monitoring by LCMS: new strategy using CDR-peptide selective proteolysis nSMOL	Takashi Shimada	Japan	Shimadzu Corporation
	6	TDM of infliximab by LC-MS/MS using nSMOL in patients with inflammatory bowel disease	Atsushi Yonezawa	Japan	Kyoto University Hospital
	7	Therapeutic drug monitoring in inflammatory bowel disease- a preliminary report from india	Alpa J. Dherai	India	P.D. Hinduja National Hospital and Medical Research Centre
	8	Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients	Karim Aouam	Tunisia	University of Monastir
	9	Allele and genotype frequencies of the cytochrome P450 genes CYP3A*1B, CYP3A4*22 and CYP3A5*3 in the Tunisian population	Karim Aouam	Tunisia	University of Monastir
10	Allele frequency of thiopurine-S-methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) genes in the Tunisian population	Karim Aouam	Tunisia	University of Monastir	
P25-8	Immunosuppressive drugs (3): Biomarkers and pharmacokinetics				
	1	Does the CYP3A biomarker 4beta-hydroxycholesterol predict tacrolimus dose early after kidney transplantation?	Elisabet Storset	Norway	Oslo University Hospital
	2	Monitoring plasmatic miRNA-155-5p expression as biomarker of prognosis of acute rejection in liver transplant recipients	Olga Millan	Spain	Hospital Clinic of Barcelona, University of Barcelona
	3	Pharmacokinetic of tacrolimus in Mexican adult patients with renal transplant: population analysis with NONMEM	Silvia Romano	Mexico	Universidad Autonoma de San Luis Potosi
	4	The regulatory effects of tacrolimus- and sirolimus-based immunosuppressive regimens on Tfh and Tfr cells in kidney transplant	Ya-Mei Li	China	West China Hospital of Sichuan University
	5	Regulation of cellular and soluble Tim-3 in renal transplant recipients treated with sirolimus- or tacrolimus-based immunosuppressive regimens	Ya-Mei Li	China	West China Hospital of Sichuan University
	6	Additional value of CYP3A5 status in a tacrolimus population pharmacokinetic model used for therapeutic drug monitoring	Jean-Baptiste Woillard	France	CHU Limoges, Univ Limoges
	7	Development of parametric and non-parametric population models and bayesian estimators for Envarsus tacrolimus formulation in liver	Jean-Baptiste Woillard	France	CHU Limoges, Univ Limoges
	8	No influence of CYP3A5*3 and CYP3A4*22 on regain of CYP3A phenotype after kidney transplantation	Kristine Hole	Norway	Diakonhjemmet Hospital
	9	FP7 BIOMARGIN preliminary results of the investigation of a small set of urinary peptides to diagnose antibody mediated rejection	Jean-Baptiste Woillard	France	CHU Limoges Univ Limoges
10	Drug-drug interaction risk assessment using PBPK modeling: inhibitory magnitude of diltiazem and its metabolite on sirolimus disposition	Chie Emoto	United States of America	Cincinnati Children's Hospital Medical Center	
P25-9	Oncologic drugs (1)				
	1	Dried plasma spot analysis for gefitinib, erlotinib, afatinib and osimertinib using high performance liquid chromatography tandem mass	Reiko Ando Makihara	Japan	National Cancer Center Hospital
	2	Development and validation of a method for the determination of paclitaxel in human plasma by high performance liquid chromatography	Marina Venzon Antunes	Brazil	Universidade Feevale
	3	Quantification of hydroxyurea in human plasma by HPLC-MS/MS and its application to pharmacokinetics in patients with chronic myeloid	Xin Hai	China	The First Affiliated Hospital of Harbin Medical University
	4	Quantification method for immune check point inhibitor, Nivolumab, using liquid chromatography tandem mass spectrometry	Irie Kei	Japan	Institute of Biomedical Research and Innovation
	5	Simultaneous quantification of 5-FU, uracil and tegafur using ultra-performance liquid chromatography coupled to tandem mass	Ken Shiraiwa	Japan	Oita University Hospital
	6	New effective and sensitive method for quantification of tamoxifen, N-desmethyl tamoxifen, 4-hydroxy tamoxifen and endoxifen in human	Gerd Ackehed	Sweden	Karolinska University Laboratory
	7	Quantification of total Dinutuximab in neuroblastoma patients with LC-MS/MS	Mohsin El Amrani	The Netherlands	University Medical Center Utrecht
	8	LC-MS/MS analysis of 5-fluorouracil in plasma for clinical research	Stephen Balloch	United Kingdom	Waters Corporation
	9	UPLC-MS/MS analysis of plasma busulfan for clinical research	Gareth Hammond	United Kingdom	Waters Corporation
10	Utility of therapeutic drug monitoring of sunitinib in patients with metastatic Renal Cell Carcinoma	Vikram Gota	India	ACTREC, Tata Memorial Centre	

Session No.	#	Presentation Title	Name	Country	Affiliation
P25-10	Oncologic drugs (2)				
	1	Retrospective investigation of concomitant medications as potential risk factors for severe neutropenia in cancer patients treated with carboplatin	Yurie Katsube	Japan	Kyoto Pharmaceutical University
	2	Molecular cloning mechanisms of multi-targeted tyrosine kinase inhibitors-induced hand-foot skin reaction based on genetic differences of	Kazuhiro Yamamoto	Japan	Kobe University Hospital
	3	To explore the clinical toxicology of intravesical chemotherapy for patients with non-invasive bladder cancer: a population-based analysis of bladder	Min-Chia Wang	Taiwan	Chi Mei Medical Center
	4	Voriconazole dosing strategies in young children: challenges and recommendations	Ferdi Sombogaard	The Netherlands	VU University Medical Center Amsterdam
	5	Open-label randomized study of individualized pharmacokinetically (PK)-guided dosing versus body surface area (BSA) dosing of paclitaxel (PTX) in	Salvatore Joseph Salamone	United States of America	Saladax Biomedical, Inc.
	6	Prohibitin 1, potential predictive marker of oxaliplatin response of colorectal cancer cells	Kanako Hara	Japan	Keio University
	7	Preclinical and clinical studies on establishment of invasive marker of dihydropyrimidine dehydrogenase activity and its usefulness in 5-	Yukako Ito	Japan	Kyoto Pharmaceutical University
	8	Impact of STAT3 genetic polymorphism on sunitinib-induced stomatitis in Japanese renal cell carcinoma patients	Aimi Watanabe	Japan	Doshisha Women's College of Liberal Arts
	9	Loss of tumor suppressor CYLD sensitizes oral squamous cell carcinoma cells to EGFR-TKI	Satoru Shinriki	Japan	Kumamoto University
10	A role of genetic polymorphisms in genes related to sunitinib and SU12662 clearance	Noriko Matsunaga	Japan	Nagasaki University Hospital	
P25-11	Clinical toxicology (1)				
	1	In vitro monoamine oxidase inhibition potential of new psychoactive substances of the alpha-methyltryptamine type	Lea Wagmann	Germany	Saarland University
	2	Mitigation of lung toxicity induced by B(a)P via modulation of oxidative stress and inflammation by carvacrol in mice	Preeti Barnwal	India	Jamia Hamdard
	3	Amelioration of radiation-induced hematological and biochemical alterations in Swiss albino mice by vernonia cinerea extract	Nitin Verma	India	Baddi University of Emerging Sciences & Technology
	4	New psychoactive substances: in vitro metabolism studies using human liver preparations compared to primary human hepatocytes and human	Lilian H. J. Richter	Germany	Saarland University
	5	Protective role of Sildenafil against carbon tetrachloride-induced nephrotoxicity by augmenting the availability of nitric oxide and	Shubham Goyal	India	Baddi University of Emerging Sciences & Technology
	6	In vitro human metabolism of the synthetic cannabinoid 5F-PY-PINACA	Hidenobu Kawashima	Japan	Gifu Pharmaceutical University and Gifu Prefectural Research Institute for Health
	7	Evaluation of toxicological risk due to the presence of bisphenol A in thermal papers	Marina Venzon Antunes	Brazil	Universidade Feevale
	8	In vitro treatment of induced pluripotent stem cells with retinoic acid for the placental drug transport evaluation model	Yuka Kawasaki	Japan	Osaka Ohtani University
9	Effectiveness of fresh frozen plasma in management of acute organophosphate intoxicated patients: an updated systematic review and	Ola Elsayed Nafea	Egypt	Zagazig University	